If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GLP-1 / glucagon dual receptor agonist (IBI362 / LY3305677)
Batch documentation
Ask sales for the Mazdutide COA matched to the offered batch. Review the recorded tests, specifications, and results against your QA and destination-market requirements before quotation.
Overview
Mazdutide, carrying development codes IBI362 (Innovent) and LY3305677 (Eli Lilly), is an investigational dual co-agonist hitting both the GLP-1 receptor and the glucagon receptor. Receptor scope is what marks it inside the multi-agonist landscape: it sits between the GIP/GLP-1 dual agonist Tirzepatide and the GIP/GLP-1/glucagon tri-agonist Retatrutide, engaging the GLP-1 and glucagon arms only, with no GIP component. This positioning makes the molecule the right tool when research needs to isolate the glucagon-pathway contribution from the GIP contribution inside the dual / tri-agonist family. Development is led by Innovent Biologics in China under license from Eli Lilly, currently in the Phase 3 DREAMS program for chronic weight management and T2DM; Chinese NMPA approval is on a faster track than Western markets. For research and pre-clinical buyers, Vialdyne releases Mazdutide acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The batch COA that comes with every released lot covers RP-HPLC peak integration and ESI-MS identity; Karl Fischer water and counter-ion quantitation are available on request and listed on the COA when tested. LC-MS/MS sequence verification is available when required by an agreed pharmacy qualification protocol: the close structural similarity within the dual-agonist class means cross-supplier identity confusion is an operationally real risk if mass-spec is the only identity gate. The 10 mg standard fill fits bench-scale aliquot work; larger fills for extended programs are scoped under change-control.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: academic and contract research laboratories.
Specifications
Nasal spray listing · US inventory
Mazdutide is also listed in this catalog as a nasal spray solution.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAMazdutide 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Not yet approved as a finished drug at the time of writing, this is an investigational compound in Phase 3 development under Innovent / Eli Lilly. It is supplied for research use only. Any commonly cited CAS should be confirmed against the batch COA.
Selected literature
Frequently asked questions
For EU and US buyers the molecule is still investigational, so there is no finished-drug approval or compendial monograph to anchor a specification. Start with the matching batch COA and compare its recorded identity and purity evidence with the buyer's written acceptance criteria. Any additional testing or regulatory file support must be agreed before quotation.
Review the storage and retest information stated on the matching batch COA and supplied record. The certificate identifies the identity and purity work actually completed. If the buyer's written procedure requires ESI-MS, RP-HPLC, sequence evidence, or another confirmation beyond that record, agree the method, reporting, timing, and cost before quotation.
Yes. Mazdutide is listed as a nasal spray solution (10 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
GLP-1 / glucagon dual receptor agonist (BI 456906)
GIP / GLP-1 / glucagon tri-agonist
Nasal spray listedCapsules listed
GIP / GLP-1 dual receptor agonist
Nasal spray listed